Preparation for International Cooperation on Cosmetics Regulations Meetings in Tokyo, Japan; Public Meeting, 38209 [E9-18321]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 146 / Friday, July 31, 2009 / Notices
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number (CMS–10078), Room
C4–26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
Dated: July 23, 2009.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E9–18378 Filed 7–30–09; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0352]
Preparation for International
Cooperation on Cosmetics
Regulations Meetings in Tokyo, Japan;
Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
PWALKER on DSK8KYBLC1PROD with NOTICES
ACTION:
Notice of public meeting.
SUMMARY: The Food and Drug
Administration (FDA) is announcing a
public meeting entitled ‘‘International
Cooperation on Cosmetics Regulations
(ICCR)—Preparation for ICCR—3
Meetings in Tokyo, Japan’’ to provide
information and receive comments on
the International Cooperation on
Cosmetics Regulations (ICCR) as well as
the upcoming meetings in Tokyo, Japan.
The topics to be discussed are the topics
for discussion at the forthcoming ICCR
steering committee meeting. The
purpose of the meeting is to solicit
public input prior to the next steering
committee and expert working group
meetings in Tokyo, Japan, scheduled for
the week of September 7, 2009.
Date and Time: The meeting will be
held on September 2, 2009, from 1:30
p.m. to 3 p.m.
Location: The meeting will be held in
University Station, rm. 2073, 4300 River
Rd., College Park, MD 20740.
Contact Person: All participants must
register with Mary Morrison, Office of
the Commissioner (HFG–1), Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, e-mail:
mary.morrison@fda.hhs.gov, FAX: 301–
827–0003.
VerDate Nov<24>2008
16:38 Jul 30, 2009
Jkt 217001
Registration and Requests for Oral
Presentations: Send registration
information (including name, title, firm
name, address, telephone, and fax
number), written material and requests
to make oral presentation, to the contact
person by August 30, 2009.
If you need special accommodations
due to a disability, please contact Mary
Morrison (see Contact Person) at least 7
days in advance.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD. A transcript will
also be available in either hardcopy or
on CD–ROM, after submission of a
Freedom of Information request. Written
requests are to be sent to the Division
of Freedom of Information (HFI–35),
Office of Management Programs, Food
and Drug Administration, 5600 Fishers
Lane, rm. 6–30, Rockville, MD 20857.
SUPPLEMENTARY INFORMATION: The
purpose of the multilateral framework
on the ICCR is to pave the way for the
removal of regulatory obstacles to
international trade while maintaining
global consumer protection.
ICCR is a voluntary international
group of cosmetics regulatory
authorities from the United States,
Japan, the European Union, and Canada.
These regulatory authority members
will enter into constructive dialogue
with their relevant cosmetics’ industry
trade associations. Currently, the ICCR
members are Health Canada; the
European Directorate General for
Enterprise and Industry; the Ministry of
Health, Labor and Welfare of Japan; and
the U.S. Food and Drug Administration.
All decisions made by the consensus
will be compatible with the laws,
policies, rules, regulations, and
directives of the respective
administrations and governments.
Members will implement and/or
promote actions or documents within
their own jurisdictions and seek
convergence of regulatory policies and
practices. Successful implementation
will require input from stakeholders.
Interested persons may present data,
information, or views orally or in
writing, on issues pending at the public
meeting. Time allotted for oral
presentations may be limited to 10
minutes. Those desiring to make oral
presentations should notify the contact
person by August 30, 2009, and submit
a brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses,
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
38209
telephone number, fax, and e-mail of
proposed participants, and an
indication of the approximate time
requested to make their presentation.
The agenda for the public meeting
will be made available on the Internet
at https://www.fda.gov/Cosmetics/
InternationalActivities/
ConferencesMeetingsWorkshops/
InternationalCooperationonCosmetics
RegulationsICCR/default.htm.
Dated: July 27, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–18321 Filed 7–30–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Insulin Binding and
Signaling.
Date: August 20, 2009.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call)
Contact Person: Lakshmanan Sankaran,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 755, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7799, ls38z@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Immunology in
Liver Disease.
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 74, Number 146 (Friday, July 31, 2009)]
[Notices]
[Page 38209]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18321]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0352]
Preparation for International Cooperation on Cosmetics
Regulations Meetings in Tokyo, Japan; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a public
meeting entitled ``International Cooperation on Cosmetics Regulations
(ICCR)--Preparation for ICCR--3 Meetings in Tokyo, Japan'' to provide
information and receive comments on the International Cooperation on
Cosmetics Regulations (ICCR) as well as the upcoming meetings in Tokyo,
Japan. The topics to be discussed are the topics for discussion at the
forthcoming ICCR steering committee meeting. The purpose of the meeting
is to solicit public input prior to the next steering committee and
expert working group meetings in Tokyo, Japan, scheduled for the week
of September 7, 2009.
Date and Time: The meeting will be held on September 2, 2009, from
1:30 p.m. to 3 p.m.
Location: The meeting will be held in University Station, rm. 2073,
4300 River Rd., College Park, MD 20740.
Contact Person: All participants must register with Mary Morrison,
Office of the Commissioner (HFG-1), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, e-mail: mary.morrison@fda.hhs.gov,
FAX: 301-827-0003.
Registration and Requests for Oral Presentations: Send registration
information (including name, title, firm name, address, telephone, and
fax number), written material and requests to make oral presentation,
to the contact person by August 30, 2009.
If you need special accommodations due to a disability, please
contact Mary Morrison (see Contact Person) at least 7 days in advance.
Transcripts: Please be advised that as soon as a transcript is
available, it will be accessible at https://www.regulations.gov. It may
be viewed at the Division of Dockets Management (HFA-305), Food and
Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD. A
transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. Written requests
are to be sent to the Division of Freedom of Information (HFI-35),
Office of Management Programs, Food and Drug Administration, 5600
Fishers Lane, rm. 6-30, Rockville, MD 20857.
SUPPLEMENTARY INFORMATION: The purpose of the multilateral framework on
the ICCR is to pave the way for the removal of regulatory obstacles to
international trade while maintaining global consumer protection.
ICCR is a voluntary international group of cosmetics regulatory
authorities from the United States, Japan, the European Union, and
Canada. These regulatory authority members will enter into constructive
dialogue with their relevant cosmetics' industry trade associations.
Currently, the ICCR members are Health Canada; the European Directorate
General for Enterprise and Industry; the Ministry of Health, Labor and
Welfare of Japan; and the U.S. Food and Drug Administration. All
decisions made by the consensus will be compatible with the laws,
policies, rules, regulations, and directives of the respective
administrations and governments. Members will implement and/or promote
actions or documents within their own jurisdictions and seek
convergence of regulatory policies and practices. Successful
implementation will require input from stakeholders.
Interested persons may present data, information, or views orally
or in writing, on issues pending at the public meeting. Time allotted
for oral presentations may be limited to 10 minutes. Those desiring to
make oral presentations should notify the contact person by August 30,
2009, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses,
telephone number, fax, and e-mail of proposed participants, and an
indication of the approximate time requested to make their
presentation.
The agenda for the public meeting will be made available on the
Internet at https://www.fda.gov/Cosmetics/InternationalActivities/ConferencesMeetingsWorkshops/InternationalCooperationonCosmeticsRegulationsICCR/default.htm.
Dated: July 27, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-18321 Filed 7-30-09; 8:45 am]
BILLING CODE 4160-01-S
